How Dulaglutide (Trulicity) Works in Plain English

What dulaglutide is

Dulaglutide is the active ingredient in Trulicity, Eli Lilly's once-weekly GLP-1 receptor agonist. It was approved by the FDA in 2014 for type 2 diabetes, and remains one of the most widely-prescribed GLP-1 drugs in U.S. diabetes care a decade later.

The mechanism is the standard GLP-1 receptor agonism that defines the entire class:

• Reduces appetite by acting on appetite centers in the brain.
• Slows gastric emptying — food stays in the stomach longer, prolonging satiety.
• Improves insulin secretion in response to high blood sugar.
• Suppresses glucagon when blood sugar is high.

What makes dulaglutide interesting is not the receptor pharmacology — it is the same GLP-1 receptor every drug in the class hits — but the engineering choice behind its long half-life.

The engineering choice: antibody fusion, not albumin binding

The fundamental problem in GLP-1 drug design: native GLP-1 has a plasma half-life of about one to two minutes. The enzyme DPP-4 degrades it almost immediately. Turning GLP-1 into a once-weekly drug requires extending that half-life by roughly 10,000 times.

The two main strategies the field has used to solve this:

1. Fatty-acid albumin binding (semaglutide, liraglutide, tirzepatide). Attach a fatty-acid chain to the peptide so it sticks to albumin in the blood, which is normally cleared slowly. This extends half-life into the days range. Semaglutide uses a C18 diacid linker that produces ~7-day half-life; liraglutide uses a shorter C16 linker that gives ~13 hours.

2. Antibody fusion (dulaglutide). Attach the GLP-1 peptide to a piece of an antibody. Antibodies persist in plasma for weeks because of how they are recycled by a special transporter called the neonatal Fc receptor (FcRn). The peptide inherits the antibody's longevity. Dulaglutide attaches two modified GLP-1 peptide analogs to a single Fc fragment of human IgG4, producing approximately a 5-day half-life.

The two strategies converge on similar practical outcomes (once-weekly dosing), but the chemistry is meaningfully different. Antibody fusion is structurally more complex and harder to manufacture; albumin binding is simpler but requires more peptide engineering to perfect.

Why dulaglutide produces less weight loss than semaglutide

This is the question most people who compare the two drugs run into. Both are once-weekly GLP-1 agonists; why does Trulicity produce only 2-4 kg of weight loss while Wegovy produces 15%+?

Two factors drive the difference:

Effective dose. The highest approved dose of dulaglutide for diabetes is 4.5 mg weekly. The Wegovy semaglutide dose for obesity is 2.4 mg weekly — but semaglutide's molecular weight is much lower than dulaglutide's (because dulaglutide includes the antibody fragment), so the effective receptor exposure at 2.4 mg semaglutide is higher than at 4.5 mg dulaglutide. The drugs are not exposure-comparable at their highest approved doses.

Indication and ceiling. Trulicity is approved only for type 2 diabetes, where the dose has been optimized for glycemic control with weight loss as a secondary benefit. There is no Trulicity-equivalent obesity formulation at a higher dose. Eli Lilly's strategic move for obesity was to develop tirzepatide (Zepbound) rather than to push dulaglutide higher.

So dulaglutide's smaller weight-loss magnitude is a product of dosing strategy rather than receptor pharmacology. At equivalent receptor activation, the effects would be similar.

What dulaglutide is best at

Dulaglutide's strongest case is in type 2 diabetes with cardiovascular risk. The REWIND cardiovascular outcomes trial (Gerstein et al., Lancet 2019) studied dulaglutide in 9,901 patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors, over a median follow-up of 5.4 years. The result: 12% reduction in major adverse cardiovascular events (HR 0.88, p=0.026).

This makes dulaglutide one of the GLP-1 drugs with the strongest cardiovascular outcomes evidence base in type 2 diabetes. SUSTAIN-6 (semaglutide) and LEADER (liraglutide) showed similar benefits in their populations, but REWIND was the largest GLP-1 cardiovascular outcomes trial and the only one to enroll a primarily primary-prevention population (patients with risk factors but not yet established cardiovascular disease).

For a type 2 diabetes patient with cardiovascular risk and the need for once-weekly dosing, dulaglutide is a robust choice supported by trial data the newer agents are still accumulating.

Where dulaglutide sits in the modern landscape

Since the approval of semaglutide (2017) and tirzepatide (2022), dulaglutide's role has narrowed:

• Where it still leads: type 2 diabetes with established CV risk where the REWIND evidence is decisive; patients who have been stable on Trulicity for years and have no compelling reason to switch.
• Where it has been displaced: weight-loss-focused use cases (semaglutide or tirzepatide are much deeper); type 2 diabetes patients where maximum glycemic effect matters (tirzepatide produces deeper HbA1c reduction).
• Real-world position: Trulicity remains one of the top-prescribed GLP-1s in U.S. diabetes care, partly due to inertia and partly due to its established CV outcomes evidence. New prescriptions skew toward semaglutide and tirzepatide.

The honest read

Dulaglutide is a clinically robust GLP-1 drug whose role has narrowed but not disappeared. The antibody-fusion design is elegant chemistry, the once-weekly profile is convenient, and the REWIND cardiovascular evidence is real. For type 2 diabetes management — particularly with CV risk — it remains a defensible choice. For maximum weight loss or the deepest HbA1c reduction, semaglutide and tirzepatide are clearly preferred.

Trulicity does not get the attention semaglutide and tirzepatide do, but it is still one of the workhorses of modern diabetes care, with a real evidence base and a real clinical position.